Lexaria Bioscience Corp. (LEXX) Insider Trading Disclosures
Lexaria Bioscience Corp. (LEXX) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: LEXX
CIK: 1348362
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 08/31
State: NV
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
MaloneBailey, LLP
Auditor SinceSince 8/31/2023 12:00:00 AM
Lead Engagement PartnerLeah Gonzales
Audit LocationHouston, Texas, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| EFFECT | 2026-10-13 | — | EFFECT Filing | 9999999995-26-003231 | View SEC Doc Filr Page |
| 424B3 | 2026-10-13 | — | 424 B3 | 0001640334-26-001670 | View SEC Doc Filr Page |
| S-3 | 2026-10-02 | — | FORM S-3 | 0001640334-26-001610 | View SEC Doc Filr Page |
| D | 2026-09-21 | — | D Filing | 0001348362-26-000002 | View SEC Doc Filr Page |
| 8-K | 2026-09-09 | 2026-09-07 | FORM 8-K | 0001640334-26-001468 | View SEC Doc Filr Page |
| 8-K | 2026-09-01 | 2026-08-28 | FORM 8-K | 0001640334-26-001437 | View SEC Doc Filr Page |
| 8-K | 2026-08-17 | 2026-08-17 | FORM 8-K | 0001640334-26-001384 | View SEC Doc Filr Page |
| 8-K | 2026-08-10 | 2026-08-04 | FORM 8-K | 0001640334-26-001302 | View SEC Doc Filr Page |
| 8-K | 2026-07-30 | 2026-07-29 | FORM 8-K | 0001640334-26-001258 | View SEC Doc Filr Page |
| 10-Q | 2026-07-13 | 2026-05-31 | FORM 10-Q | 0001640334-26-001166 | View SEC Doc Filr Page |
| 10-Q | 2026-04-13 | 2026-02-28 | FORM 10-Q | 0001640334-26-000687 | View SEC Doc Filr Page |
| 4 | 2026-03-18 | 2026-03-17 | PRIMARY DOCUMENT | 0001103780-26-000001 | View SEC Doc Filr Page |
| 8-K | 2026-02-06 | 2026-02-04 | FORM 8-K | 0001640334-26-000230 | View SEC Doc Filr Page |
| 8-K | 2026-01-28 | 2026-01-27 | FORM 8-K | 0001640334-26-000162 | View SEC Doc Filr Page |
| S-8 | 2026-01-28 | — | FORM S-8 | 0001640334-26-000159 | View SEC Doc Filr Page |
| EFFECT | 2026-01-14 | — | EFFECT Filing | 9999999995-26-000171 | View SEC Doc Filr Page |
| 424B3 | 2026-01-14 | — | 424B3 | 0001640334-26-000089 | View SEC Doc Filr Page |
| 25-NSE | 2026-01-14 | — | 25-NSE Filing | 0001354457-26-000039 | View SEC Doc Filr Page |
| 10-Q | 2026-01-13 | 2025-11-30 | FORM 10-Q | 0001640334-26-000080 | View SEC Doc Filr Page |
| S-3 | 2025-12-29 | — | FORM S-1 | 0001640334-25-002382 | View SEC Doc Filr Page |
| D | 2025-12-19 | — | D Filing | 0001348362-25-000018 | View SEC Doc Filr Page |
| 8-K | 2025-12-16 | 2025-12-14 | FORM 8-K | 0001640334-25-002348 | View SEC Doc Filr Page |
| 424B5 | 2025-12-16 | — | 424B5 | 0001640334-25-002331 | View SEC Doc Filr Page |
| DEF 14A | 2025-12-10 | 2026-01-27 | FORM DEF 14A | 0001640334-25-002275 | View SEC Doc Filr Page |
| EFFECT | 2025-12-09 | — | EFFECT Filing | 9999999995-25-003607 | View SEC Doc Filr Page |